Product Name | Lapaquistat acetate (Synonyms: TAK-475) |
---|---|
CAS | 189060-13-7 |
Formula | C33H41ClN2O9 |
MW | 645.14 |
MDL | MFCD06407873 |
Appearance | White to off-white powder |
Storage condition | Store short-term at 0-4°C or long-term at -20°C in a dry, dark place. |
Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
---|---|---|---|---|
1 mg | 3-5 days | $216.00 | Visible after login | |
2 mg | 3-5 days | $326.00 | Visible after login | |
5 mg | 3-5 days | $518.00 | Visible after login |
Product Name | Lapaquistat acetate (Synonyms: TAK-475) |
---|---|
CAS | 189060-13-7 |
Formula | C33H41ClN2O9 |
MW | 645.14 |
MDL | MFCD06407873 |
Appearance | White to off-white powder |
Storage condition | Store short-term at 0-4°C or long-term at -20°C in a dry, dark place. |
Lapaquistat acetate, a potent squalene synthase inhibitor, impedes the conversion of farnesyl diphosphate (FPP) to squalene, a key step in cholesterol synthesis. Utilized in treating Mevalonate Kinase Deficiency (MKD), an autosomal recessive disorder, it significantly reduces low-density lipoprotein cholesterol levels. However, its use may be accompanied by liver damage, a known side effect that warrants monitoring.
Repositioning of Tak-475 In Mevalonate Kinase Disease: Translating Theory Into Practice
PMID: 28901277 DOI: 10.2174/0929867324666170911161417
Br J Pharmacol. 2008 Jul;154(5):949-57.
PMID: 21518985 DOI: 10.1161/CIRCULATIONAHA.110.975284